23andMe
phase results dose duration of treatment | 23andMe
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
25 of 39
Related slides by other companies
Alkermes
Results
June 2021
artistry phase efficacy expansion initiated following determination of subcutaneous | Alkermes
Kymera
Investor Presentation
June 2023
phase dose and expansion trial to evaluate in adult patients with liquid and solid tumors | Kymera
Aeglea BioTherapeutics
Investor Presentation
May 2023
interim results from phase clinical trial lowering of | Aeglea BioTherapeutics
MindMed
Investor Presentation
December 2024
for gad phase study designs | MindMed
Other recent decks by 23andMe
See all presentations (7 decks)
Investor Presentation
April 2023
Investor Presentation
August 2022
Investor Presentation
February 2022
Investor Day
January 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io